Early treatment: PreCISe-ly what the patient needs

Journal of the Neurological Sciences
Xavier Montalban

Abstract

Multiple sclerosis usually begins in young adulthood, and presents in 80-90% of patients with an initial disease course typified by relapses and remissions. The ability to recognise an individual's first neurological episode, commonly called a clinically isolated syndrome (CIS), represents a significant advance in the differential diagnosis of multiple sclerosis and offers the possibility of intervening at an earlier stage. Of note, over eighty percent of patients with a clinically isolated syndrome and magnetic resonance imaging lesions go on to develop multiple sclerosis within three years. The effect of first line therapies has been shown to be more pronounced when they are used at disease onset compared to a more advanced disease stage. First-line therapeutics have reached a milestone where a significant portion of disease activity is either preventable or at least modifiable. The results of the PreCISe Phase III multicentre, double-blind, randomised trial of glatiramer acetate versus placebo in patients with clinically isolated syndrome with abnormal MRI have recently been published. The study demonstrated a significant delay in progression to clinically definite multiple sclerosis in patients receiving glatiramer acetate,...Continue Reading

References

Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
Mar 1, 1997·Brain : a Journal of Neurology·B FergusonV H Perry
Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Jul 30, 1999·Journal of Neuroimmunology·B D TrappA Chang
Mar 20, 2001·Journal of Neurology, Neurosurgery, and Psychiatry·P A BrexD H Miller
May 30, 2001·Lancet·G ComiUNKNOWN Early Treatment of Multiple Sclerosis Study Group
Jun 13, 2001·Neurology·UNKNOWN Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Sep 11, 2002·Neurology·J A CohenUNKNOWN IMPACT Investigators
Sep 24, 2002·Brain : a Journal of Neurology·Tanja KuhlmannWolfgang Brück
Jan 23, 2003·Brain : a Journal of Neurology·M FilippiA Falini
Nov 24, 2004·Neurology·Hillel PanitchUNKNOWN North American Study Group on Interferon beta-1b in Secondary Progressive MS
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Dec 20, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·W RashidD H Miller
May 13, 2009·Archives of Neurology·Alex RoviraXavier Montalban
Jan 8, 2010·Neurology·X MontalbanD H Miller
Apr 17, 2013·Journal of Neurology·Douglas L ArnoldSamson Antel

❮ Previous
Next ❯

Citations

Dec 19, 2015·Pharmacogenetics and Genomics·Ekaterina TsarevaOlga Favorova

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.